title: Repeated treatment with S. aureus superantigens expands the survival rate of Ehrlich ascites tumor bearing mice.
abstract: The bacterial superantigen Staphylococcal enterotoxin-A (SEA), produced by some strains of Staphylococcus aureus, causes proliferation of cytotoxic T-lymphocytes and cytokine production in vivo. SEA has been shown to be highly efficient for antibody-targeted superantegen immunotherapy for different tumor models. A candidate B-cell superantigen that has received considerable attention these days is staphylococcal protein-A (PA). It has been shown to possess multiple immunological responses. The anti-tumor property of PA is well documented in the literature in various transplantable tumors of rats and mice. In the present study, we have shown that the T-cell superantigen SEA and B-cell superantigen PA induce immunomodulatory and anti-tumor activity which is strongly protentiated by PA + SEA co-administration. Combination treatment with PA and SEA prolongs the immune response in vivo, limits the development of immunological unresponsiveness and promotes maximum anti-tumor effects to tumor carrying animals, as compared with PA or SEA alone. The immune response after combined therapy is characterized by substantially augmented IFN-gamma, TNF-alpha, Nitric oxide and strong CTL activity. Our data demonstrate that combined PA + SEA therapy induces long-term survival of the animals, carrying the Ehrlich ascites tumor.
authors: Immunotechnology Section, Bose Institute, Calcutta, India. mondal@wadsworth.org
authors: Tapan K
authors: TK
authors: Mondal
authors: D
authors: D
authors: Bhatta
authors: Surojit
authors: S
authors: Biswas
authors: Prakriti
authors: P
authors: Pal
mesh_terms: D000818:Animals; D018941:Antigens, CD19; D018952:Antigens, CD34; D015415:Biomarkers; D001854:Bone Marrow Cells / Q000166:cytology / Q000276:immunology; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy / Q000276:immunology*; D003601:Cytotoxicity Tests, Immunologic; D004195:Disease Models, Animal; D004768:Enterotoxins / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000096:biosynthesis; D007375:Interleukin-1 / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D008297:Male; D051379:Mice; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013205:Staphylococcal Protein A / Q000627:therapeutic use*; D013211:Staphylococcus aureus; D018089:Superantigens / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D018941:Antigens, CD19; D018952:Antigens, CD34; D015415:Biomarkers; D004768:Enterotoxins; D007375:Interleukin-1; D013205:Staphylococcal Protein A; D018089:Superantigens; C026066:enterotoxin A, Staphylococcal; D007371:Interferon-gamma